Evidence map›Paper›PMID 41422434›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Synthesis of Bispecific Conjugates by ADP-Ribosyl Cyclases.

Sunny H Kim, Arshad J Ansari, Lei Zhang, Guoyun Kao, Thuc Oanh Hoang, Zeyu Zhang, Srinivasarao Singireddi, Benjamin B Katz, Yong Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sunny H KimDepartment of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA.ORCID https://orcid.org/0009-0006-6086-6561
Arshad J AnsariDepartment of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0002-2493-9544
Lei ZhangDepartment of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA.
Guoyun KaoDepartment of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA.
Thuc Oanh HoangDepartment of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA.
Zeyu ZhangDepartment of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA.
Srinivasarao SingireddiDepartment of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA.
Benjamin B KatzDepartment of Chemistry, University of California, Irvine, CA, USA.
Yong ZhangDepartment of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0002-3132-8557

Funding

Chemistry and Biology of ADP-Ribosylation-Dependent SignalingR35GM137901 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Yong Zhang · 2020 to 2026
$2.5M
Reprogramming Exosomes for Biomedical ApplicationsR01EB031830 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZHANG, YONG · 2021 to 2024
$2.1M
Reprogramming Exosomes for Novel Immunotherapy of Triple Negative Breast CancerR01CA276240 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Yong Zhang · 2023 to 2026
$2.0M
NCI NIH HHS R01 CA276240NCI NIH HHS R01CA276240NIBIB NIH HHS R01 EB031830NIBIB NIH HHS R01EB031830NIGMS NIH HHS R35 GM137901NIGMS NIH HHS R35GM137901
6 · The paper itself

Abstract

Armed with two distinct targeting moieties, artificially created bispecific agents can uniquely modulate various processes and events implicated in human health and diseases. Despite recent approvals of multiple bispecific therapeutics, generation of homogeneous dual-targeting constructs with desired pharmacological properties remains technically challenging. Here, we report a strategy for synthesis of bispecific agents by utilizing CD38, a member of the ADP-ribosyl cyclase family, and its covalent inhibitor. A model ADP-ribosyl cyclase-enabled bispecific conjugate (ARC-BsC) against human T-cell CD3 and prostate-specific membrane antigen (PSMA) is generated through site-specific conjugation of an anti-CD3 antibody-CD38 fusion with the CD38 covalent inhibitor derivatized by a PSMA small-molecule ligand. The resulting ARC-BsC can redirect and activate cytotoxic T cells toward killing PSMA-expressing tumor cells, eliciting highly potent and selective anti-cancer immunity in vitro and in vivo. This proof-of-concept work demonstrates ARC-BsC as a potentially general approach for the development of bispecific therapeutics with diverse applications.

Indexed as

ADP-ribosyl CyclaseAntibodies, BispecificAnimalsAntigens, SurfaceCD3 ComplexCell Line, TumorGlutamate Carboxypeptidase IIHumansMiceADP-ribosyl CyclaseAntibodies, BispecificAntigens, SurfaceCD3 ComplexFOLH1 protein, humanGlutamate Carboxypeptidase IIBispecific conjugateCD38immunotherapyprostate cancer

Identifiers

PMID41422434
PMCPMC12955874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.